按MRP4计算的前列腺素外流的结构基础
Sergei Pourmal1,2,3, Evan Green1,4,5, Ruchika Bajaj6
1Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA.
Nature structural & molecular biology
|January 12, 2024
概括
多种药物耐药性蛋白4 (MRP4) 携带像前列腺体这样的信号分子. 化-EM结构显示出一个共同的结合点和一个全性机制,有助于设计针对MRP4的药物.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 结构生物学 结构生物学
背景情况:
- 多种药物耐药性蛋白4 (MRP4) 是一种ATP结合的磁带载体.
- MRP4 独特地运输的是前列腺素,这是来自不和脂肪酸的信号分子.
研究的目的:
- 为了阐明MRP4的基质选择性.
- 了解MRP4.4的传输机制.
主要方法:
- 低温电子显微镜 (cryo-EM) 用于确定纳米盘重建的MRP4.4的六个结构.
- 在运输周期的各个阶段捕获了结构,包括基质结合状态和与ATP-Mg2+结合的催化受损突变体.
主要成果:
- 与PGE1,PGE2和DHEA-S结合的基质结合结构揭示了各种有机离子的共同结合点.
- 提出了一种用于基质诱导的MRP4 ATPase活性增强的全性机制.
- 一个触媒性损害的MRP4突变结构显示出一个向外封闭的形状,表明一个交替访问的传输机制.
结论:
- 这项研究提供了对MRP4.4内源性功能的结构性见解.
- 这些发现为开发针对MRP4的药物奠定了基础.
相关概念视频
Carrier-Mediated Transport
436
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
436
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
441
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
441
IP3/DAG Signaling Pathway
12.1K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.1K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
40
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
40
GPCR Desensitization
6.0K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.0K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
430
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
430


